The subject matter disclosed herein relates to materials used in medical implants, and more particularly, to a leaflet that includes at least one layer of a composite material that includes an expanded polytetrafluoroethylene (ePTFE) membrane containing serpentine fibrils and an elastomer. The elastomer may be located in all or substantially all of the pores of the ePTFE membrane.
Artificial heart valves desirably last at least ten years in vivo. To last that long, artificial heart valves should exhibit sufficient durability for at least four hundred million cycles or more. The valves, and more specifically heart valve leaflets, must resist structural degradation including the formation of holes, tears, and the like as well as adverse biological consequences such as calcification and thrombosis.
Fluoropolymers, such as expanded and non-expanded forms of polytetrafluoroethylene (PTFE), modified PTFE, and copolymers of PTFE, offer a number of desirable properties, including excellent inertness and superior biocompatibility, and therefore make ideal candidate materials for artificial heart valves. Additionally, PTFE and expanded PTFE (ePTFE) have been used to create heart valve leaflets. It has been shown, however, that PTFE stiffens with repeated flexure, which can lead to unacceptable flow performance. Failure due to formation of holes and tears in the material has also been observed. A variety of polymeric materials has previously been employed as prosthetic heart valve leaflets. Failure of these polymeric leaflets due to stiffening and hole formation typically occurred within two years of implant. Efforts to improve leaflet durability by thickening the leaflets resulted in unacceptable hemodynamic performance of the valves, that is, the pressure drop across the open valve was too high. Conventional leaflets also experience wrinkling, which can be sites of potential failure of the heart valve.
Thus, there remains a need in the art for a biocompatible artificial heart valve, including leaflets, that is durable and reduces the occurrence of wrinkles during the cycling of the heart valve between open and closed configurations.
According to an embodiment, a prosthetic valve is provided for regulating blood flow direction in a human patient. Such a prosthetic valve includes, but is not limited to, a cardiac valve or a venous valve.
Embodiments provided herein utilize fluoropolymer membranes that exhibit significant elongation while substantially retaining the strength properties of the fluoropolymer membrane. Such fluoropolymer membranes characteristically possess serpentine fibrils.
Other embodiments provide a prosthetic valve for regulating blood flow direction within a patient that includes a leaflet having at least one layer of a composite material that contains at least one expanded fluoropolymer membrane having serpentine fibrils and an elastomer. In embodiments, the elastomer is present in all or substantially all of the pores of the fluoropolymer membrane. The fluoropolymer membrane may have a microstructure of substantially only serpentine fibrils. In some embodiments, the expanded fluoropolymer membrane includes a plurality of serpentine fibrils. In addition, the fluoropolymer may be polytetrafluoroethylene. The leaflet may be formed of a single layer or multiple layers of the composite material. Additionally, the leaflets may be operatively connected to a support structure and movable between open and closed configurations relative to the support structure to form a heart valve. The elasticity within the leaflets permits the leaflets to bend with a reduced occurrence of wrinkling as the valve opens and closes. Leaflets formed of the composite material exhibit no visible signs of holes, tears, or delamination and remain otherwise unchanged after actuation of the leaflet for at least 100 million cycles.
Other embodiments provide an implantable prosthetic valve for regulating blood flow direction in a patient that includes a leaflet cyclable between a closed configuration to substantially prevent blood flow through the prosthetic valve and an open configuration to allow blood flow through the prosthetic valve. The leaflet is formed of at least one layer of a composite material that includes at least one expanded fluoropolymer membrane having serpentine fibrils and an elastomer. The elastomer is present in all or substantially all of the pores of the expanded fluoropolymer membrane. In addition, the expanded fluoropolymer membrane may include a microstructure of substantially only serpentine fibrils. The expanded fluoropolymer membrane may include a plurality of serpentine fibrils. In some embodiments, the fluoropolymer is polytetrafluoroethylene. The leaflet has a reduced occurrence of wrinkling in the open and closed configurations of the prosthetic valve. Additionally, the leaflet may be may be coupled to a rigid or an elastic support structure in a conventional manner to form a heart valve.
Embodiments provided herein provide a method of forming a leaflet of an implantable prosthetic valve for regulating blood flow direction in a patient that includes providing a composite material that includes at least one expanded fluoropolymer membrane having serpentine fibrils and an elastomer and bringing at least one layer of the composite material into contact with additional layers of the composite material by wrapping a sheet of the composite material with a starting and ending point defined as an axial seam adhered to itself. The elastomer may be present in all or substantially all of the pores of the expanded fluoropolymer membrane. In accordance with an embodiment, the elastic properties of the leaflet are present in the axial direction of the leaflet. The fluoropolymer may be polytetrafluoroethylene. Also, the expanded fluoropolymer membrane may include a microstructure of substantially only serpentine fibrils. In accordance with another embodiment, the expanded fluoropolymer membrane includes a plurality of serpentine fibrils.
Other embodiments provide an implantable prosthetic valve for regulating blood flow direction in a patient that includes a support structure and a leaflet formed of at least one layer that includes a composite material containing at least one expanded fluoropolymer membrane having serpentine fibrils and an elastomer. The expanded fluoropolymer membrane includes a plurality of pores and the elastomer is present in all or substantially all of the pores. Additionally, the leaflet is movable relative to the support structure and is cyclable between a closed configuration and an open configuration. The leaflet has a reduced occurrence of wrinkling in both the open and closed configurations. In some embodiments, the fluoropolymer is polytetrafluoroethylene. The expanded fluoropolymer membrane may include a microstructure of substantially only serpentine fibrils. The expanded fluoropolymer membrane may include a plurality of serpentine fibrils.
Other embodiments provide an prosthetic valve that includes a leaflet having at least one layer comprising a composite material that exhibits an increase in stiffness when elongated to at least about 30% strain. The composite material includes at least one expanded fluoropolymer membrane and an elastomer. The expanded fluoropolymer membrane may include serpentine fibrils. Also, the expanded fluoropolymer membrane may include a plurality of serpentine fibrils. In an embodiment, the expanded fluoropolymer membrane includes a plurality of pores and the elastomer is present in substantially all of the pores.
An embodiment of a method of forming a leaflet includes providing a composite material that exhibits an increase in stiffness when elongated to at least about 30% strain and bringing at least one layer of the composite material into contact with additional layers of the composite material by wrapping a sheet of the composite material with a starting and ending point defined as an axial seam adhered to itself. The composite material includes at least one expanded fluoropolymer membrane and an elastomer, and, in some embodiments, may include serpentine fibrils.
Leaflets formed with the composite material may be operatively coupled to a support structure and movable between closed and open configurations relative to the support structure to form a heart valve.
Leaflets in accordance with embodiments provided herein demonstrate a reduction of wrinkling as the heart valves cycle between an open configuration and a closed configuration.
Embodiments provided herein provide that the elastomer may be present in all or substantially all of the pores of the fluoropolymer membrane.
Other embodiments provide that additional materials may be incorporated into the pores of the expanded fluoropolymer membrane or between the layers of the composite material forming the leaflet to enhance desired properties of the leaflet.
References will now be made to embodiments illustrated in the drawings and specific language which will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the invention is thereby intended, such alterations and further modifications in the illustrated methods and apparatus, as such further applications of the principles of the invention as illustrated therein as being contemplated as would normally occur to one skilled in the art to which the invention relates.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. In the drawings, the thickness of the lines, layers, and regions may be exaggerated for clarity. Like numbers found throughout the figures denote like elements.
As used herein, the term “serpentine fibrils” means multiple fibrils that curve or turn one way then another.
As used herein, the term “controlled retraction” refers to causing articles to shorten in length in at least one direction by the application of heat, by wetting with a solvent, or by any other suitable means or combinations thereof in such a way as to inhibit folding, pleating, or wrinkling of the subsequent article visible to the naked eye.
The term “wrinkling” also refers to the appearance of the composite material upon bending or flexing of the otherwise wrinkle-free composite material forming the leaflet.
As used herein, the term “wrinkle-free” is meant to denote that the composite material is free of wrinkles prior to bending or flexing the composite material.
The term “imbibed or imbibing” as used herein is meant to describe any means for at least partially filling at least a portion of the pores of a porous material such as ePTFE or the like.
The term “elongation” or “elongated” as used herein is meant to denote the increase in length in response to the application of a force.
The term “leaflet” as used herein is meant to denote a component of a prosthetic valve for regulating blood flow direction. Leaflets according to the present embodiments are formed of one or more layers of a composite material including an expanded fluoropolymer membrane having serpentine fibrils and an elastomer.
The term “elastic” as used herein refers to the property of a material to be elongated upon the application of a force and that returns to its approximate original dimensions upon the release of the force due to the retraction force of the material.
The term “increase in stiffness” as used herein refers the increase in resistance to further elongation once the stop-point is reached.
The terms “node” and “fibril” as used herein refers to particular characteristic shapes of elements of the structure of an expanded fluoropolymer membrane, as is known in the art of expanded fluoropolymer membranes.
In one embodiment, fluoropolymer membranes that exhibit high elongation while substantially retaining the strength properties of the fluoropolymer membrane are utilized. Such membranes characteristically possess serpentine fibrils, such as the idealized serpentine fibril exemplified in
The high elongation is enabled by forming relatively straight fibrils into serpentine fibrils that substantially straighten upon the application of a force in a direction opposite to the compressed direction. The creation of the serpentine fibrils can be achieved through a thermally-induced controlled retraction of the expanded polytetrafluoroethylene (ePTFE), through wetting the article with a solvent, such as, but not limited to, isopropyl alcohol or Fluorinert® (a perfluorinated solvent commercially available from 3M, Inc., St. Paul, Minn.), or by a combination of these two techniques. The retraction of the article does not result in visible pleating, folding, or wrinkling of the ePTFE, unlike what occurs during mechanical compression. The retraction also can be applied to very thin membranes, unlike known methods. During the retraction process, the fibrils not only become serpentine in shape but also may also increase in width.
The precursor materials can be biaxially expanded ePTFE membranes. In one embodiment, materials such as those made in accordance with the general teachings of U.S. Pat. No. 7,306,729 to Bacino, et al. are suitable precursor membranes, especially if small pore size articles are desired. These membranes may possess a microstructure of substantially only fibrils. The precursor membrane may or may not be amorphously locked. The precursor membrane may also be at least partially filled, coated, imbibed, or otherwise combined with additional materials (e.g., elastomeric materials).
The precursor membrane may be restrained in one or more directions during the retraction process in order to prescribe the desired amount of elongation of the final article. The amount of elongation is directly related to, and determined by, the amount of retraction.
In one embodiment, retraction can be achieved in a uniaxial tenter frame by positioning the rails at a distance less than the width of the precursor membrane prior to the application of heat or solvent or both. When using a biaxial tenter frame, one or both of the sets of grips, pins, or other suitable attachment means can similarly be positioned at a distance less than the dimensions of the precursor membrane. It is to be appreciated that these retraction means differ from the mechanical compression taught by the House and Sowinski patents noted above. Upon retraction, the expanded fluoropolymer membrane possesses serpentine fibrils. These retracted membranes characteristically possess serpentine fibrils and are substantially wrinkle free. In some exemplary embodiments, the retracted membranes may possess a microstructure of substantially only serpentine fibrils. In at least one embodiment, the fluoropolymer membranes include a plurality of serpentine fibrils. As used herein, the phrase “plurality of serpentine fibrils” is meant to denote the presence of 2 or more, 5 or more, 10 or more, or 15 or more serpentine fibrils in the fluoropolymer membrane within a field of view as taught below.
At least one elastomeric material can be added to the precursor membrane prior, during, or subsequent to retraction to form a composite. In the absence of such elastomeric materials, fluoropolymer articles having serpentine fibrils do not exhibit appreciable recovery after elongation. Suitable elastomeric materials may include, but are not limited to, PMVE-TFE (perfluoromethylvinyl ether-tetrafluoroethylene) copolymers, PAVE-TFE (perfluoro (alkyl vinyl ether)-tetrafluoroethylene) copolymers, silicones, polyurethanes, and the like. It is to be noted that PMVE-TFE and PAVE-TFE are fluoroelastomers. Other fluoroelastomers are suitable elastomeric materials. The resultant retracted article not only possesses high elongation while substantially retaining the strength properties of the fluoropolymer membrane, it also possesses an additional property of low percent unrecoverable strain energy density. These retracted articles can exhibit percent unrecoverable strain energy density values less than about 90%, less than about 85%, less than about 80%, less than about 70%, less than about 60%, and lower, including any and all percentages therebetween.
In one embodiment, a composite material including an expanded fluoropolymer membrane having serpentine fibrils and an elastomer as described above forms the leaflet materials of a heart valve. The composite material is substantially free of wrinkles. It is to be appreciated that the use of a single layer or multiple layers of the expanded fluoropolymer membrane and multiple types of elastomeric materials are considered to be within the scope of the present disclosure. Additional materials may also be incorporated into the pores of the expanded fluoropolymer membrane and/or between layers of the composite material forming the leaflet to enhance desired properties of the leaflet. The fluoropolymer membrane exhibits significant elongation while substantially retaining the strength properties of the fluoropolymer membrane.
The composite material provides performance attributes required for use in high-cycle flexural implant applications, such as heart valve leaflets, in several significant ways. For example, the inclusion of the elastomer improves the fatigue performance of the leaflet by eliminating or reducing stiffening that is typically observed with ePTFE-only materials. In addition, the incorporation of an elastomer reduces the likelihood that the material will undergo permanent set deformation, such as wrinkling or creasing, that could result in compromised performance.
Composite materials of embodiments herein not only exhibit elongation, but also exhibit a dramatic increase in stiffness after achieving a high, optionally predetermined, elongation. As a consequence, the composite materials can be elongated to a point at which further elongation is inhibited by the dramatic increase in stiffness. The composite material has a stop point at which further elongation occurs only in conjunction with a significant increase in pressure or force. The composite material exhibits an increase in stiffness when elongated to at least about 30% strain, to at least about 35% strain, to at least about 40% strain, to at least about 45% strain, to at least about 50% strain, to at least about 55% strain, and even greater.
As discussed above, the elastomer may be combined with the expanded fluoropolymer membrane such that the elastomer occupies all or substantially all of the pores within the expanded fluoropolymer membrane. The term “substantially all of the pores” as used herein is meant to denote that the elastomer is present in at least a portion of all or nearly all of the pores of the expanded fluoropolymer (ePTFE) membrane. Having elastomer present in all or substantially all of the pores of the fluoropolymer membrane reduces the space in which foreign materials can be undesirably incorporated into the composite material. An example of such a foreign material is calcium. For instance, if calcium becomes incorporated into the composite material used in a heart valve leaflet, mechanical damage can occur during cycling, which can lead to the formation of holes in the leaflet and degradation in hemodynamics. On the other hand, the incorporation of additional, desired materials into the pores of the expanded fluoropolymer membrane and/or between layers of the composite material forming the leaflet can enhance desired properties of the leaflet, and are considered to be within the scope of the invention.
Leaflets constructed from the composite material can be assembled in a variety of configurations based on desired laminate or leaflet thickness and number of layers of composite material. Leaflets according to some embodiments may be composed of a single layer of the composite material or multiple layers of the composite material. Multi-layers provide for enhanced durability and increased damage reduction to the leaflet. The maximum number of layers within the leaflet is determined, at least in part, by the desired thickness of the leaflet. The leaflet has a ratio of thickness (μm) to number of layers of composite material of less than about 5. In addition, the leaflets may be affixed to a rigid or an elastic frame in a conventional manner, such as, for example, to form a heart valve.
The elasticity within the leaflet greatly reduces the occurrence of wrinkles as the heart valves cycle between an open configuration and a closed configuration. The elastic properties of the leaflet may be present in the axial direction of the leaflet. By “axial direction of the leaflet”, it is meant that the direction from the base of the leaflet to the free edge of the leaflet. In addition, the leaflets may have elastic properties in other, non-axial, direction(s). Thus, leaflets formed with the inventive composite material demonstrate a reduction in wrinkling as they bend and flex with the opening and closing of a heart valve. In addition, the elasticity of the leaflet slows accelerations and reduces the forces imposed on the leaflet, thereby extending the life of the leaflet. Leaflets formed of the composite material exhibit no visible signs of holes, tears, or delamination and have unchanged performance after actuation of the leaflet to at least 100 million cycles, and even to at least 200 million cycles.
Additionally, the elastic properties of the leaflet improve bending properties and reduce closure stresses. Bending properties generally refer to the qualitative amount of wrinkles and/or creases developed with in the leaflet structure during deformations induced by cyclic opening and closing.
Having generally described various embodiments, a further understanding can be obtained by reference to certain specific examples illustrated below which are provided for purposes of illustration only and are not intended to be all inclusive or limiting unless otherwise specified.
It should be understood that although certain methods and equipment are described below, any method or equipment determined suitable by one of ordinary skill in the art may be alternatively utilized.
Membrane samples were die cut to form rectangular sections about 2.54 cm by about 15.24 cm to measure the weight (using a Mettler-Toledo analytical balance model AG204) and thickness (using a Käfer Fz1000/30 snap gauge). Using these data, density was calculated with the following formula: ρ=m/(w*l*t), in which: ρ=density (g/cm3), m=mass (g), w=width (cm), l=length (cm), and t=thickness (cm). The average of three measurements was reported.
Tensile break load was measured using an INSTRON 122 tensile test machine equipped with flat-faced grips and a 0.445 kN load cell. The gauge length was about 5.08 cm and the cross-head speed was about 50.8 cm/min. The sample dimensions were about 2.54 cm by about 15.24 cm. For highest strength measurements, the longer dimension of the sample was oriented in the highest strength direction. For the orthogonal MTS measurements, the larger dimension of the sample was oriented perpendicular to the highest strength direction. Each sample was weighed using a Mettler Toledo Scale Model AG204, then the thickness was measured using the Käfer FZ1000/30 snap gauge; alternatively, any suitable means for measuring thickness may be used. The samples were then tested individually on the tensile tester. Three different sections of each sample were measured. The average of the three maximum loads (i.e., peak force) measurements was reported. The longitudinal and transverse matrix tensile strengths (MTS) were calculated using the following equation: MTS=(maximum load/cross-section area)*(bulk density of PTFE)/(density of the porous membrane), where the bulk density of the PTFE was taken to be about 2.2 g/cm3.
Composite tensile testing was performed using an RSA3 dynamic mechanical analyzer (TA Instruments, New Castle, Del.) with a 3500 g load cell. 13 mm×39 mm rectangular samples were mounted with a 20 mm gauge length and strained at a rate of 1000%/minute. For highest strength measurements, the longer dimension of the sample was oriented in the highest strength direction. For the orthogonal tensile strength measurements, the larger dimension of the sample was oriented perpendicular to the highest strength direction. Reported data are an average of at least 3 measurements.
Elongation of the retracted article can be measured by any suitable application of tensile force, such as, for example, by the use of a tensile testing machine, by hand, or by applying internal pressure to a tubular article. In the embodiments presented herein, elongation was performed at a rate of about 10% per second in all directions that were elongated. Elongation was calculated as the final length minus the initial length, divided by the initial length, and was reported as a percentage. The average of three measurements was reported.
The percent unrecoverable strain energy density of composites was measured using an RSA3 dynamic mechanical analyzer (TA Instruments, New Castle, Del.) with a 3500 g load cell. A 13 mm×39 mm rectangular sample was cut so that the longer dimension was oriented in the highest strength direction. The sample was mounted in film/fiber tension grips with a 20 mm gauge length. The grips were programmed to elongate the sample to 50% strain at a rate of 200 mm/minute and were then immediately returned to the initial displacement at a rate of 200 mm/minute. Load and displacement values were collected, converted to stress and strain values, and then graphed. The unrecoverable strain energy density is represented by the first area 101 between the elongation and return curve as depicted in
The percent unrecoverable strain energy density of the sample is defined by the first area 101 between the elongation and return curve as shown in
Should the sample break prior to 50% strain, then another sample should be tested at 50% of the breakage strain to calculate the unrecoverable strain energy density. For samples that are too small to accommodate the 20 mm grip separation and allow enough material within the grips to prevent slippage of the sample within the grips, other combinations of crosshead speed and grip separation may be used provided the ratio of crosshead speed to initial grip separation is equal to 10 minutes.
Scanning electron micrographs were created choosing magnifications suitable for identifying fibrils. Articles that have been retracted in accordance with the teachings herein may require elongation in the direction of retraction in order to identify the serpentine fibrils. For the purposes of identifying the number of serpentine fibrils, a field of view of 7 microns by 7 microns of the sample is to be employed.
For porous fluoropolymer leaflets having pores substantially filled with elastomer, the elastomer can be dissolved or degraded and rinsed away using an appropriate solvent in order to measure or examine desired properties.
For instance, the fluoroelastomer component of a leaflet as described in Example 1 can be partially or substantially removed to enable SEM imaging of the ePTFE structure. The sample is restrained from shrinking and submerged in 95 g of Fluorinert Electronic Liquid FC-72 (3M Inc., St. Paul, Minn.) and allowed to soak without agitation. After approximately one hour, the fluorinated solvent is poured off and replaced with 95 g of fresh solvent. This process is repeated for a total of 5 soaking cycles, the first 4 cycles for approximately 1 hour, and the 5th cycle for approximately 24 hours.
To aid in the removal of elastomer, the sample can also be agitated using an ultrasonic cleaner (e.g. Branson 200 Ultrasonic Cleaner (Model—B200)).
A heart valve having polymeric leaflets was formed from a composite material having an expanded fluoropolymer membrane and an elastomeric material as described above; joined to a metallic balloon expandable support structure; and was constructed according to the following process.
A support structure 1001, in the form of a metallic balloon expandable structure, was laser machined from a length of 316LVM stainless steel annealed tube with an outside diameter of 25.4 mm and a wall thickness of 0.502 mm. A pattern was cut into the tube to form a cylindrically-shaped cut stent frame, also referred to as the support structure 1001, as illustrated in the flat plane view of
Next, the support structure 1001 was electro-polished, which resulted in 0.025 mm material removal from each surface and left the edges rounded. The corners of support structure 1001 that would be in contact with the leaflet material were rounded using a rotary sander. The support structure 1001 was exposed to a surface roughening step to improve the adherence of leaflets to the support structure 1001, without degrading fatigue durability performance. The support structure 1001 was rinsed with water and then subjected to a plasma cleaning treatment using methods commonly known to those of ordinary skill in the art. The support structure 1001 was dipped into a 4% solution of a fluoroelastomer in PF5080, 3M, St. Paul, Minn., USA and allowed to air dry. The fluoroelastomer was formulated according to the general teachings described in U.S. Pat. No. 7,462,675 to Chang, et al. Additional fluoroelastomers may be suitable and are described in U.S. Publication No. 2004/0024448 to Chang, et al.
The fluoroelastomer consists essentially of between about 65 and 70 weight percent perfluoromethyl vinyl ether and complementally about 35 and 30 weight percent tetrafluoroethylene.
A composite material was then prepared having a membrane layer of biaxially expanded ePTFE imbibed with a fluoroelastomer. More specifically, the membrane layer of ePTFE was manufactured according to the general teachings described in U.S. Pat. No. 7,306,729. The ePTFE membrane was tested in accordance with the methods described previously. The biaxially expanded ePTFE membrane that was not amorphously locked, and had the following properties was used: thickness=0.0025 mm, density=0.236 g/cc, matrix tensile strength in the strongest direction=386 MPa, matrix tensile strength in the direction orthogonal to the strongest direction=218 MPa, elongation at maximum load in the strongest direction=24%, and elongation at maximum load in the direction orthogonal to the strongest direction=38.1%. The percent weight of the fluoroelastomer within the composite material was about 74%.
This membrane was imbibed with the fluoroelastomer described previously in this example. The fluoroelastomer was dissolved in PF5080 (3M, St Paul, Minn.) in an about 4% concentration. The solution was coated using a mayer bar onto the ePTFE membrane (while being supported by a polyethylene release film) and dried in a convection oven
A 20 mm wide strip of the composite material was rolled into a fiber and spirally wrapped around each stent frame post 1006 on the support structure 1001 of
A mandrel 1101 was machined from aluminum in a generally cylindrical shape shown as in
The mandrel 1101 had forty-eight 0.5 mm diameter vent holes in the form of pocket vent holes 1107 and surface vent holes 1108. Twelve pocket vent holes 1107 were positioned at the bottom of each of the irregular shallow pockets 1105 that pass from the irregular shallow pockets 1105 to a central cavity 1106 running within the center of the mandrel 1101. Thirty-six surface vent holes 1108 were distributed across the outer surface 1104 of the mandrel 1101 that pass from the outer surface 1104 to the central cavity 1106. In a subsequent step, these pocket vent holes 1107 and surface vent holes 1108 allow for trapped air to be vented away from a valve during a molding process.
An elastomeric composite of ePTFE membrane and a fluoroelastomer was made as described hereafter. The fluoroelastomer previously described in this example was dissolved in a fluorinated solvent (Fluorinert® Electronic Liquid FC-72, 3M Inc., St. Paul, Minn.) in a ratio of 3 parts copolymer to 97 parts solvent by weight. A continuous slot die coating process operating at a line speed of approximately 1.8 m/min and a solution coating rate of approximately 96 g/min was utilized to imbibe this solution into an ePTFE membrane that was fed from a roll.
A biaxially expanded ePTFE membrane that had not been amorphously locked, and having the following properties was used: thickness=0.0025 mm, density=0.236 g/cc, matrix tensile strength in the strongest direction=386 MPa, matrix tensile strength in the direction orthogonal to the strongest direction=218 MPa, elongation at maximum load in the strongest direction=24%, and elongation at maximum load in the direction orthogonal to the strongest direction=38.1%.
The imbibed ePTFE membrane was restrained in the clamps of a heated, uniaxial tenter frame where the length direction corresponded with the strongest direction of the membrane, and fed into a 2.4 m long heated chamber.
The rails of the tenter frame were positioned to accommodate a 100 mm wide imbibed ePTFE membrane entering the heated chamber, enabling the heated composite to shrink due to the application of heat so that it exited the chamber with an approximate 56 mm width. The line speed was set to provide a dwell time of about 45 seconds within the heated chamber and the material reached a maximum temperature of approximately 180° C., thereby driving off substantially all of the fluorosolvent.
This imbibing process enabled the copolymer to at least partially penetrate the pores of the membrane and to create a coating of the copolymer on the surface of the membrane
The stress of this elastomeric composite was about 43 MPa. The stress-strain curve is shown as
Four layers of this elastomeric composite were wrapped circumferentially around the mandrel 1101. The elastomeric composite was pierced using sharp pointed tweezers above each of the 48 vent holes.
The support structure 1001, which is a metallic balloon expandable structure, with composite fiber wrapped posts was slid over the elastomeric composite and mandrel 1101 and was positioned as shown in
A 0.025 mm thick film of the fluoroelastomer previously described was obtained. A 3 mm wide strip of this fluoroelastomer film was positioned on top of the leaflet closed cells 1004 of the support structure 1001. Additional strips of fluoroelastomer film with widths of 10, 15, and 20 mm were sequentially positioned on top of each of the stent frame posts 1006. Eight additional layers of the elastomeric composite were wrapped around the mandrel 1101 and all the previously applied components.
A sacrificial composite material comprising ePTFE and polyimide with a thickness of approximately 0.004 mm was wrapped around the mandrel and previously applied components. Adhesive-backed polyimide tape was used to attach the ePTFE/polyimide composite to the mandrel at each end and to seal the longitudinal seam.
The mandrel 1102 with previously applied components was then mounted in a pressure vessel so that the central cavity 1106 was plumbed to atmosphere. The central cavity 1106 extended from the first end 1102 axially through the mandrel 1101 and communicates to the 48 previously described pocket vent holes 1107 and surface vent holes 1108.
About 414 KPa (60 psi) of helium pressure was applied to the pressure vessel, forcing the ePTFE/fluoroelastomer composite material against the mandrel 1101 and the support structure 1001. Heat was applied to the pressure vessel until the temperature inside the mandrel reached about 264° C., about 55 minutes later. The heat was removed and the pressure vessel was allowed to cool to room temperature. This process thermally bonded the layers of ePTFE/fluoroelastomer composite material to each other and to the support structure 1001. The pressure was released and the mandrel was removed from the pressure vessel. The valve assembly was slid off of the mandrel 1101 and the sacrificial ePTFE/polyimide composite material was removed.
A horizontal slit was made through the ePTFE/elastomer composite material near the upper ring of the support structure 1001. Small sheets of 0.76 mm thick FEP film were pressed against each of the three leaflets and clamped in place using hemostats so that the valve assumed a closed shape. The valve was placed in an oven at 180° C. for 15 minutes while held in this position.
After removing the FEP sheets, the valve leaflets were trimmed to their final length and excess ePTFE/elastomer composite was trimmed around the support structure, which resulted in a valve 800 as shown in
The performance of the leaflets 802 in this valve 800 were characterized on a real-time pulse duplicator that measured typical anatomical pressures and flows across the valve 800, generating an initial or “zero fatigue” set of data for that particular valve 800. The valve 800 was then transferred to a high-rate fatigue tester and was subjected to approximately 200 million cycles.
The flow performance was characterized by the following process:
The valve 800 was pressed into a silicone annular ring to allow the valve 800 to be subsequently evaluated in a real-time pulse duplicator.
The potted valve 800 was then placed into a real-time left heart flow pulse duplicator system. The flow pulse duplicator system included the following components supplied by VSI Vivitro Systems Inc., Victoria BC, Canada: a Super Pump, Servo Power Amplifier Part Number SPA 3891; a Super Pump Head, Part Number SPH 5891B, 38.320 cm2 cylinder area; a valve station/fixture; a Wave Form Generator, TriPack Part Number TP 2001; a Sensor Interface, Part Number VB 2004; a Sensor Amplifier Component, Part Number AM 9991; and a Square Wave Electro Magnetic Flow Meter, Carolina Medical Electronics Inc., East Bend, N.C., USA.
In general, the flow pulse duplicator system uses a fixed displacement, piston pump to produce a desired fluid flow through the valve 800 under test.
The heart flow pulse duplicator system was adjusted to produce the desired flow, mean pressure, and simulated pulse rate. The valve 800 under test was then cycled for about 5 to 20 minutes.
Pressure and flow data were measured and collected during the test period, including ventricular pressures, aortic pressures, flow rates, and pump piston position.
The valve 800 in this example had a pressure drop of 5.2 mm Hg, EOA of 2.97 and regurgitant fraction of 14.4%
The durability of the leaflets 802 in this example were evaluated in a high rate fatigue tester (Six Position Heart Valve Durability Tester, Part Number M6 was supplied by Dynatek, Galena, Mo.) and was driven by a Dynatek Dalta DC 7000 Controller. This high rate fatigue tester displaces fluid through a valve 800 with a typical cycle rate of about 780 cycles per minute. During the test, the valve 800 can be visually examined using a tuned strobe light. The leaflets 802 were tested to 200 million cycles with no visible signs of holes, tears, or delamination in the leaflets 802.
One of the leaflets 802 was cut from the support structure 1001. The elastomer was removed as described in the test method set forth above. It is noted that the elastomer does not need to be fully removed from the leaflet 802 to reveal the serpentine fibrils.
The percent unrecoverable strain energy density of the leaflet 802 was determined to be about 86.6% and is depicted by the area bound by the elongation and return curves in
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modification, and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice in the art to which the invention pertains and as may be applied to the essential features hereinbefore set forth, and as fall within the scope of the invention and the limits of the appended claims.
This application is a divisional of U.S. patent application Ser. No. 14/181,965, filed Feb. 17, 2014, which claims the benefit of U.S. Provisional Application 61/779,891, filed Mar. 13, 2013, both of which are incorporated herein by reference in their entireties for all purposes. This application is also a continuation-in-part of U.S. patent application Ser. No. 13/485,823, filed May 31, 2012, now U.S. Pat. No. 8,945,212, issued Feb. 3, 2015, and is also a continuation-in-part of U.S. patent application Ser. No. 13/078,774, filed Apr. 1, 2011, now U.S. Pat. No. 8,961,599, granted Feb. 24, 2015, both of which are incorporated herein by reference in their entireties for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
654799 | Levett | Jul 1900 | A |
1851314 | Knoche | Mar 1932 | A |
3625451 | Anderson | Dec 1971 | A |
3915167 | Waterman | Oct 1975 | A |
3953566 | Gore | Apr 1976 | A |
4222126 | Boretos et al. | Sep 1980 | A |
4265694 | Boretos et al. | May 1981 | A |
4339831 | Johnson | Jul 1982 | A |
4340091 | Skelton et al. | Jul 1982 | A |
4349498 | Ellis et al. | Sep 1982 | A |
4425908 | Simon | Jan 1984 | A |
4626255 | Reichart et al. | Dec 1986 | A |
4629459 | Ionescu et al. | Dec 1986 | A |
4655246 | Phlipot et al. | Apr 1987 | A |
4692369 | Nomi | Sep 1987 | A |
4731074 | Rousseau et al. | Mar 1988 | A |
4851000 | Gupta | Jul 1989 | A |
4858810 | Intlekofer et al. | Aug 1989 | A |
4877661 | House et al. | Oct 1989 | A |
4955899 | Della Corna et al. | Sep 1990 | A |
5026513 | House et al. | Jun 1991 | A |
5071609 | Roger et al. | Dec 1991 | A |
5217486 | Rice et al. | Jun 1993 | A |
5325746 | Anderson | Jul 1994 | A |
5344427 | Cottenceau et al. | Sep 1994 | A |
5397355 | Marin et al. | Mar 1995 | A |
5476589 | Bacino | Dec 1995 | A |
5491704 | Duron | Feb 1996 | A |
5527338 | Purdy | Jun 1996 | A |
5534007 | St. Germain et al. | Jul 1996 | A |
5549663 | Cottone | Aug 1996 | A |
5554183 | Nazari | Sep 1996 | A |
5562726 | Chuter | Oct 1996 | A |
5693083 | Baker et al. | Dec 1997 | A |
5707376 | Kavteladze et al. | Jan 1998 | A |
5708044 | Branca | Jan 1998 | A |
5709704 | Nott et al. | Jan 1998 | A |
5713917 | Leonhardt et al. | Feb 1998 | A |
5713948 | Uflacker | Feb 1998 | A |
5718973 | Lewis et al. | Feb 1998 | A |
5720776 | Chuter et al. | Feb 1998 | A |
5725552 | Kotula et al. | Mar 1998 | A |
5759192 | Saunders | Jun 1998 | A |
5769884 | Solovay | Jun 1998 | A |
5772884 | Tanaka et al. | Jun 1998 | A |
5776141 | Klein et al. | Jul 1998 | A |
5776186 | Uflacker | Jul 1998 | A |
5782909 | Quiachon et al. | Jul 1998 | A |
5824043 | Cottone | Oct 1998 | A |
5824050 | Karwoski et al. | Oct 1998 | A |
5843158 | Lenker et al. | Dec 1998 | A |
5843161 | Solovay | Dec 1998 | A |
5843162 | Inoue | Dec 1998 | A |
5904703 | Gilson | May 1999 | A |
5935162 | Dang | Aug 1999 | A |
5961546 | Robinson et al. | Oct 1999 | A |
6010529 | Herweck et al. | Jan 2000 | A |
6013093 | Nott et al. | Jan 2000 | A |
6013854 | Moriuchi | Jan 2000 | A |
6015431 | Thornton et al. | Jan 2000 | A |
6019785 | Strecker | Feb 2000 | A |
6027779 | Campbell et al. | Feb 2000 | A |
6042588 | Munsinger et al. | Mar 2000 | A |
6042606 | Frantzen | Mar 2000 | A |
6143021 | Staehle | Nov 2000 | A |
6152144 | Lesh et al. | Nov 2000 | A |
6165195 | Wilson | Dec 2000 | A |
6174331 | Moe et al. | Jan 2001 | B1 |
6190406 | Duerig et al. | Feb 2001 | B1 |
6214025 | Thistle et al. | Apr 2001 | B1 |
6224627 | Armstrong et al. | May 2001 | B1 |
6231561 | Frazier et al. | May 2001 | B1 |
6231581 | Shank et al. | May 2001 | B1 |
6231589 | Wessman et al. | May 2001 | B1 |
6245012 | Kleshinski | Jun 2001 | B1 |
6245939 | Yu Wei et al. | Jun 2001 | B1 |
6261320 | Tam et al. | Jul 2001 | B1 |
6264671 | Stack et al. | Jul 2001 | B1 |
6273900 | Nott et al. | Aug 2001 | B1 |
6283994 | Moe et al. | Sep 2001 | B1 |
6322585 | Khosravi et al. | Nov 2001 | B1 |
6328727 | Frazier et al. | Dec 2001 | B1 |
6346117 | Greenhalgh | Feb 2002 | B1 |
6352561 | Leopold et al. | Mar 2002 | B1 |
6451396 | Zumbrum et al. | Mar 2002 | B1 |
6372870 | Kitahara et al. | Apr 2002 | B1 |
6436132 | Patel et al. | Aug 2002 | B1 |
6451051 | Drasler et al. | Sep 2002 | B2 |
6485513 | Fan | Nov 2002 | B1 |
6488701 | Nolting et al. | Dec 2002 | B1 |
6491704 | Gifford et al. | Dec 2002 | B2 |
6524335 | Hartley et al. | Feb 2003 | B1 |
6527779 | Rourke | Mar 2003 | B1 |
6541589 | Baillie | Apr 2003 | B1 |
6551303 | Van et al. | Apr 2003 | B1 |
6551350 | Thornton et al. | Apr 2003 | B1 |
6562069 | Cai et al. | May 2003 | B2 |
6572643 | Gharibadeh | Jun 2003 | B1 |
6572646 | Boylan et al. | Jun 2003 | B1 |
6620190 | Colone | Sep 2003 | B1 |
6626939 | Burnside et al. | Sep 2003 | B1 |
6652556 | Vantassel et al. | Nov 2003 | B1 |
6666885 | Moe | Dec 2003 | B2 |
6673455 | Zumbrum et al. | Jan 2004 | B2 |
6689150 | Vantassel et al. | Feb 2004 | B1 |
6705563 | Luo et al. | Mar 2004 | B2 |
6712836 | Berg et al. | Mar 2004 | B1 |
6712842 | Gifford et al. | Mar 2004 | B1 |
6726715 | Sutherland | Apr 2004 | B2 |
6730108 | Van et al. | May 2004 | B2 |
6730120 | Berg et al. | May 2004 | B2 |
6743210 | Hart et al. | Jun 2004 | B2 |
6746472 | Frazier et al. | Jun 2004 | B2 |
6755854 | Gillick et al. | Jun 2004 | B2 |
6755856 | Seibold et al. | Jun 2004 | B2 |
6755857 | Peterson et al. | Jun 2004 | B2 |
6758858 | McCrea et al. | Jul 2004 | B2 |
6770579 | Dawson | Aug 2004 | B1 |
6776604 | Chobotov et al. | Aug 2004 | B1 |
6827731 | Armstrong et al. | Dec 2004 | B2 |
6866669 | Buzzard et al. | Mar 2005 | B2 |
6884259 | Tran et al. | Apr 2005 | B2 |
6926732 | Derus et al. | Aug 2005 | B2 |
6939352 | Buzzard et al. | Sep 2005 | B2 |
6945990 | Greenan | Sep 2005 | B2 |
6949113 | Van et al. | Sep 2005 | B2 |
6953332 | Kurk et al. | Oct 2005 | B1 |
6974471 | Van et al. | Dec 2005 | B2 |
6994092 | Van et al. | Feb 2006 | B2 |
7033368 | Rourke | Apr 2006 | B2 |
7044134 | Khairkhahan et al. | May 2006 | B2 |
7049380 | Chang | May 2006 | B1 |
7052511 | Weldon et al. | May 2006 | B2 |
7066951 | Chobotov | Jun 2006 | B2 |
7083642 | Sirhan et al. | Aug 2006 | B2 |
7105018 | Yip et al. | Sep 2006 | B1 |
7122050 | Randall et al. | Oct 2006 | B2 |
7128073 | Van et al. | Oct 2006 | B1 |
7147657 | Chiang et al. | Dec 2006 | B2 |
7169160 | Middleman et al. | Jan 2007 | B1 |
7198636 | Cully et al. | Apr 2007 | B2 |
7208003 | Davis et al. | Apr 2007 | B2 |
7238200 | Lee et al. | Jul 2007 | B2 |
7252680 | Freitag | Aug 2007 | B2 |
7306729 | Bacino et al. | Dec 2007 | B2 |
7331992 | Randall et al. | Feb 2008 | B2 |
7396359 | Derowe et al. | Jul 2008 | B1 |
7419678 | Falotico | Sep 2008 | B2 |
7448122 | Kokish et al. | Nov 2008 | B1 |
7462675 | Chang et al. | Dec 2008 | B2 |
7531611 | Sabol et al. | May 2009 | B2 |
7555034 | Shin et al. | Jun 2009 | B2 |
7566336 | Corcoran et al. | Jul 2009 | B2 |
7572289 | Sisken et al. | Aug 2009 | B2 |
7601159 | Ewers et al. | Oct 2009 | B2 |
7611528 | Goodson et al. | Nov 2009 | B2 |
7628803 | Pavcnik et al. | Dec 2009 | B2 |
7655034 | Mitchell et al. | Feb 2010 | B2 |
7678123 | Chanduszko | Mar 2010 | B2 |
7771455 | Ken | Aug 2010 | B2 |
7789908 | Sowinski | Sep 2010 | B2 |
7803186 | Li et al. | Sep 2010 | B1 |
7811314 | Fierens et al. | Oct 2010 | B2 |
7815591 | Levine et al. | Oct 2010 | B2 |
7815763 | Fierens et al. | Oct 2010 | B2 |
7833565 | O'Connor | Nov 2010 | B2 |
7846179 | Belef et al. | Dec 2010 | B2 |
7887580 | Randall et al. | Feb 2011 | B2 |
7927364 | Fierens et al. | Apr 2011 | B2 |
7927365 | Fierens et al. | Apr 2011 | B2 |
7935141 | Randall et al. | May 2011 | B2 |
7967829 | Gunderson et al. | Jun 2011 | B2 |
7976575 | Hartley | Jul 2011 | B2 |
7998189 | Koelbel et al. | Aug 2011 | B2 |
8029557 | Sobrino-Serrano | Oct 2011 | B2 |
8029559 | Sisken et al. | Oct 2011 | B2 |
8029563 | House et al. | Oct 2011 | B2 |
8048440 | Chang et al. | Nov 2011 | B2 |
8062349 | Moore et al. | Nov 2011 | B2 |
8080032 | Van et al. | Dec 2011 | B2 |
8157810 | Case et al. | Apr 2012 | B2 |
8167935 | McGuckin et al. | May 2012 | B2 |
8231650 | Cully et al. | Jul 2012 | B2 |
8241350 | Randall et al. | Aug 2012 | B2 |
8273105 | Cohen et al. | Sep 2012 | B2 |
8287583 | Laduca et al. | Oct 2012 | B2 |
8349000 | Schreck | Jan 2013 | B2 |
8424166 | Dorneman et al. | Apr 2013 | B2 |
8449595 | Ouellette et al. | May 2013 | B2 |
8469990 | McGuckin et al. | Jun 2013 | B2 |
8475512 | Hunt | Jul 2013 | B2 |
8523897 | Van et al. | Sep 2013 | B2 |
8529597 | Linder et al. | Sep 2013 | B2 |
8585757 | Agathos | Nov 2013 | B2 |
8637144 | Ford | Jan 2014 | B2 |
8685055 | Vantassel et al. | Apr 2014 | B2 |
8709077 | Schreck | Apr 2014 | B2 |
8801746 | Kreidler et al. | Aug 2014 | B1 |
8834519 | Van et al. | Sep 2014 | B2 |
8870947 | Shaw | Oct 2014 | B2 |
8945212 | Bruchman et al. | Feb 2015 | B2 |
8961599 | Bruchman et al. | Feb 2015 | B2 |
9109310 | Baaijens et al. | Aug 2015 | B2 |
9254204 | Roeder et al. | Feb 2016 | B2 |
9314249 | Kreidler et al. | Apr 2016 | B2 |
9504565 | Armstrong | Nov 2016 | B2 |
9554806 | Larsen et al. | Jan 2017 | B2 |
9554900 | Bruchman et al. | Jan 2017 | B2 |
9597086 | Larsen et al. | Mar 2017 | B2 |
9743932 | Amplatz et al. | Aug 2017 | B2 |
9744033 | Bruchman et al. | Aug 2017 | B2 |
9770327 | Bruchman et al. | Sep 2017 | B2 |
9795475 | Bruchman et al. | Oct 2017 | B2 |
9801712 | Bruchman et al. | Oct 2017 | B2 |
10022219 | Bruchman et al. | Jul 2018 | B2 |
10342658 | Bruchman et al. | Jul 2019 | B2 |
10470878 | Bruchman et al. | Nov 2019 | B2 |
20010037142 | Stelter et al. | Nov 2001 | A1 |
20010051824 | Hopkins et al. | Dec 2001 | A1 |
20020007208 | Strecker | Jan 2002 | A1 |
20020029077 | Leopold et al. | Mar 2002 | A1 |
20020045936 | Moe | Apr 2002 | A1 |
20020055773 | Campbell et al. | May 2002 | A1 |
20020091439 | Baker et al. | Jul 2002 | A1 |
20020099431 | Armstrong et al. | Jul 2002 | A1 |
20020151953 | Chobotov et al. | Oct 2002 | A1 |
20020198588 | Armstrong et al. | Dec 2002 | A1 |
20020198594 | Schreck | Dec 2002 | A1 |
20030004559 | Lentz et al. | Jan 2003 | A1 |
20030004560 | Chobotov et al. | Jan 2003 | A1 |
20030012905 | Zumbrum et al. | Jan 2003 | A1 |
20030023303 | Palmaz et al. | Jan 2003 | A1 |
20030040771 | Hyodoh et al. | Feb 2003 | A1 |
20030055492 | Shaolian et al. | Mar 2003 | A1 |
20030055495 | Pease et al. | Mar 2003 | A1 |
20030055496 | Cai et al. | Mar 2003 | A1 |
20030057156 | Peterson et al. | Mar 2003 | A1 |
20030060871 | Hill et al. | Mar 2003 | A1 |
20030097175 | O'Connor et al. | May 2003 | A1 |
20030098383 | Luo et al. | May 2003 | A1 |
20030114917 | Holloway et al. | Jun 2003 | A1 |
20030139806 | Haverkost et al. | Jul 2003 | A1 |
20030149467 | Linder et al. | Aug 2003 | A1 |
20030181942 | Sutton et al. | Sep 2003 | A1 |
20030211264 | Farnsworth et al. | Nov 2003 | A1 |
20030229394 | Ogle et al. | Dec 2003 | A1 |
20040019374 | Hojeibane et al. | Jan 2004 | A1 |
20040024442 | Sowinski et al. | Feb 2004 | A1 |
20040024448 | Chang et al. | Feb 2004 | A1 |
20040034366 | Van et al. | Feb 2004 | A1 |
20040044361 | Frazier et al. | Mar 2004 | A1 |
20040054396 | Hartley et al. | Mar 2004 | A1 |
20040073289 | Hartley | Apr 2004 | A1 |
20040093070 | Hojeibane et al. | May 2004 | A1 |
20040122503 | Campbell et al. | Jun 2004 | A1 |
20040138734 | Chobotov et al. | Jul 2004 | A1 |
20040143315 | Bruun et al. | Jul 2004 | A1 |
20040167619 | Case et al. | Aug 2004 | A1 |
20040176839 | Huynh et al. | Sep 2004 | A1 |
20040260393 | Rahdert et al. | Dec 2004 | A1 |
20050038470 | Van et al. | Feb 2005 | A1 |
20050049667 | Arbefeuille et al. | Mar 2005 | A1 |
20050070820 | Boutillette et al. | Mar 2005 | A1 |
20050080476 | Gunderson et al. | Apr 2005 | A1 |
20050085890 | Rasmussen et al. | Apr 2005 | A1 |
20050113861 | Corcoran et al. | May 2005 | A1 |
20050125031 | Pipenhagen et al. | Jun 2005 | A1 |
20050137682 | Justino | Jun 2005 | A1 |
20050240257 | Ishimaru et al. | Oct 2005 | A1 |
20050261765 | Liddicoat | Nov 2005 | A1 |
20050283224 | King | Dec 2005 | A1 |
20050288767 | Kujawski et al. | Dec 2005 | A1 |
20060004433 | Greenberg et al. | Jan 2006 | A1 |
20060015171 | Armstrong | Jan 2006 | A1 |
20060036311 | Nakayama et al. | Feb 2006 | A1 |
20060058833 | Vancamp et al. | Mar 2006 | A1 |
20060058889 | Case et al. | Mar 2006 | A1 |
20060135947 | Soltesz et al. | Jun 2006 | A1 |
20060155366 | Laduca et al. | Jul 2006 | A1 |
20060190074 | Hill et al. | Aug 2006 | A1 |
20060254569 | Chipman | Nov 2006 | A1 |
20060259133 | Sowinski et al. | Nov 2006 | A1 |
20060264980 | Khairkhahan et al. | Nov 2006 | A1 |
20060265053 | Hunt | Nov 2006 | A1 |
20060276883 | Greenberg et al. | Dec 2006 | A1 |
20060276888 | Lee et al. | Dec 2006 | A1 |
20060290027 | O'Connor et al. | Dec 2006 | A1 |
20070012624 | Bacino et al. | Jan 2007 | A1 |
20070027528 | Agnew | Feb 2007 | A1 |
20070027535 | Purdy et al. | Feb 2007 | A1 |
20070060999 | Randall et al. | Mar 2007 | A1 |
20070066993 | Kreidler | Mar 2007 | A1 |
20070067021 | Haverkost et al. | Mar 2007 | A1 |
20070088424 | Greenberg et al. | Apr 2007 | A1 |
20070100427 | Perouse | May 2007 | A1 |
20070118209 | Strecker | May 2007 | A1 |
20070118210 | Pinchuk | May 2007 | A1 |
20070129786 | Beach et al. | Jun 2007 | A1 |
20070162048 | Quinn et al. | Jul 2007 | A1 |
20070167955 | Arnault et al. | Jul 2007 | A1 |
20070198077 | Cully et al. | Aug 2007 | A1 |
20070198078 | Berra et al. | Aug 2007 | A1 |
20070208421 | Quigley | Sep 2007 | A1 |
20070213800 | Fierens et al. | Sep 2007 | A1 |
20070219467 | Clark et al. | Sep 2007 | A1 |
20070248640 | Karabey et al. | Oct 2007 | A1 |
20070249980 | Carrez et al. | Oct 2007 | A1 |
20070250146 | Cully et al. | Oct 2007 | A1 |
20070250153 | Cully et al. | Oct 2007 | A1 |
20070254012 | Ludwig et al. | Nov 2007 | A1 |
20070255390 | Ducke et al. | Nov 2007 | A1 |
20070270891 | McGuckin, Jr. | Nov 2007 | A1 |
20070288087 | Fearnot et al. | Dec 2007 | A1 |
20080027529 | Hartley et al. | Jan 2008 | A1 |
20080033527 | Nunez et al. | Feb 2008 | A1 |
20080033534 | Cook et al. | Feb 2008 | A1 |
20080039925 | Ishimaru et al. | Feb 2008 | A1 |
20080051876 | Ta et al. | Feb 2008 | A1 |
20080091261 | Long et al. | Apr 2008 | A1 |
20080114440 | Hlavka et al. | May 2008 | A1 |
20080119943 | Armstrong et al. | May 2008 | A1 |
20080125711 | Alpini et al. | May 2008 | A1 |
20080133004 | White | Jun 2008 | A1 |
20080147111 | Johnson et al. | Jun 2008 | A1 |
20080178434 | Bulanda | Jul 2008 | A1 |
20080200977 | Paul et al. | Aug 2008 | A1 |
20080208329 | Bishop et al. | Aug 2008 | A1 |
20080269785 | Lampropoulos et al. | Oct 2008 | A1 |
20080319531 | Doran et al. | Dec 2008 | A1 |
20090004239 | Ladet et al. | Jan 2009 | A1 |
20090005854 | Huang et al. | Jan 2009 | A1 |
20090030499 | Bebb et al. | Jan 2009 | A1 |
20090036976 | Beach et al. | Feb 2009 | A1 |
20090043373 | Arnault de la Menardiere et al. | Feb 2009 | A1 |
20090048656 | Wen | Feb 2009 | A1 |
20090054723 | Khairkhahan et al. | Feb 2009 | A1 |
20090062838 | Brumleve et al. | Mar 2009 | A1 |
20090082844 | Zacharias et al. | Mar 2009 | A1 |
20090099596 | McGuckin et al. | Apr 2009 | A1 |
20090099640 | Weng | Apr 2009 | A1 |
20090112249 | Miles et al. | Apr 2009 | A1 |
20090157175 | Benichou | Jun 2009 | A1 |
20090171386 | Amplatz et al. | Jul 2009 | A1 |
20090182413 | Burkart et al. | Jul 2009 | A1 |
20090187197 | Roeber et al. | Jul 2009 | A1 |
20090216308 | Hartley | Aug 2009 | A1 |
20090216321 | Osborne et al. | Aug 2009 | A1 |
20090259291 | Kolbel et al. | Oct 2009 | A1 |
20100011564 | Millwee et al. | Jan 2010 | A1 |
20100016943 | Chobotov | Jan 2010 | A1 |
20100023048 | Mach | Jan 2010 | A1 |
20100023114 | Chambers et al. | Jan 2010 | A1 |
20100057195 | Roeder et al. | Mar 2010 | A1 |
20100094394 | Beach et al. | Apr 2010 | A1 |
20100094401 | Kolbel et al. | Apr 2010 | A1 |
20100094405 | Cottone | Apr 2010 | A1 |
20100106240 | Duggal et al. | Apr 2010 | A1 |
20100159171 | Clough | Jun 2010 | A1 |
20100190254 | Chian et al. | Jul 2010 | A1 |
20100211052 | Brown et al. | Aug 2010 | A1 |
20100248324 | Xu et al. | Sep 2010 | A1 |
20100249922 | Li et al. | Sep 2010 | A1 |
20100280591 | Shin et al. | Nov 2010 | A1 |
20110039690 | Niu | Feb 2011 | A1 |
20110040366 | Goetz et al. | Feb 2011 | A1 |
20110049757 | O'Connor | Mar 2011 | A1 |
20110054515 | Bridgeman et al. | Mar 2011 | A1 |
20110054519 | Neuss | Mar 2011 | A1 |
20110064781 | Cleek et al. | Mar 2011 | A1 |
20110066221 | White et al. | Mar 2011 | A1 |
20110125252 | Goddard et al. | May 2011 | A1 |
20110130821 | Styrc | Jun 2011 | A1 |
20110142804 | Gaudette et al. | Jun 2011 | A1 |
20110218619 | Benichou et al. | Sep 2011 | A1 |
20110250689 | Baaijens et al. | Oct 2011 | A1 |
20110311746 | Ma et al. | Dec 2011 | A1 |
20110313503 | Berra et al. | Dec 2011 | A1 |
20120022630 | Wubbeling | Jan 2012 | A1 |
20120022638 | Leewood et al. | Jan 2012 | A1 |
20120046652 | Sokel | Feb 2012 | A1 |
20120058100 | Shastri et al. | Mar 2012 | A1 |
20120061314 | Choi et al. | Mar 2012 | A1 |
20120065667 | Javois et al. | Mar 2012 | A1 |
20120078357 | Conklin | Mar 2012 | A1 |
20120116496 | Chuter et al. | May 2012 | A1 |
20120123529 | Levi et al. | May 2012 | A1 |
20120123530 | Carpentier et al. | May 2012 | A1 |
20120129150 | Carbonell | May 2012 | A1 |
20120130473 | Norris et al. | May 2012 | A1 |
20120130474 | Buckley | May 2012 | A1 |
20120130475 | Shaw | May 2012 | A1 |
20120143242 | Masters | Jun 2012 | A1 |
20120143305 | Berra et al. | Jun 2012 | A1 |
20120172927 | Campbell et al. | Jul 2012 | A1 |
20120172965 | Kratzberg et al. | Jul 2012 | A1 |
20120172968 | Chuter et al. | Jul 2012 | A1 |
20120253450 | Case et al. | Oct 2012 | A1 |
20120253453 | Bruchman | Oct 2012 | A1 |
20120283585 | Werneth et al. | Nov 2012 | A1 |
20120283773 | Van et al. | Nov 2012 | A1 |
20120290082 | Quint et al. | Nov 2012 | A1 |
20120296360 | Norris et al. | Nov 2012 | A1 |
20120296418 | Bonyuet et al. | Nov 2012 | A1 |
20120323211 | Ogle et al. | Dec 2012 | A1 |
20120323270 | Lee | Dec 2012 | A1 |
20120323315 | Bruchman et al. | Dec 2012 | A1 |
20130023981 | Dierking et al. | Jan 2013 | A1 |
20130046371 | Greenberg et al. | Feb 2013 | A1 |
20130073029 | Shaw | Mar 2013 | A1 |
20130123896 | Bloss et al. | May 2013 | A1 |
20130123908 | Hinchliffe et al. | May 2013 | A1 |
20130138138 | Clark et al. | May 2013 | A1 |
20130150947 | Kaufman et al. | Jun 2013 | A1 |
20130158647 | Norris et al. | Jun 2013 | A1 |
20130166021 | Bruchman et al. | Jun 2013 | A1 |
20130178889 | Miles et al. | Jul 2013 | A1 |
20130184807 | Kovach et al. | Jul 2013 | A1 |
20130197631 | Bruchman et al. | Aug 2013 | A1 |
20130245666 | Larsen et al. | Sep 2013 | A1 |
20130245742 | Norris | Sep 2013 | A1 |
20130296912 | Ottma | Nov 2013 | A1 |
20130310924 | Groothuis et al. | Nov 2013 | A1 |
20130331929 | Mitra et al. | Dec 2013 | A1 |
20140005773 | Wheatley | Jan 2014 | A1 |
20140012303 | Heipl | Jan 2014 | A1 |
20140018841 | Peiffer et al. | Jan 2014 | A1 |
20140031927 | Bruchman et al. | Jan 2014 | A1 |
20140046360 | Van et al. | Feb 2014 | A1 |
20140135817 | Tischler et al. | May 2014 | A1 |
20140135897 | Cully et al. | May 2014 | A1 |
20140142617 | Larsen et al. | May 2014 | A1 |
20140163671 | Bruchman et al. | Jun 2014 | A1 |
20140163673 | Bruchman et al. | Jun 2014 | A1 |
20140172066 | Goepfrich et al. | Jun 2014 | A1 |
20140172080 | Bruchman et al. | Jun 2014 | A1 |
20140172081 | Bruchman et al. | Jun 2014 | A1 |
20140172082 | Bruchman et al. | Jun 2014 | A1 |
20140172083 | Bruchman et al. | Jun 2014 | A1 |
20140180400 | Bruchman et al. | Jun 2014 | A1 |
20140180402 | Bruchman et al. | Jun 2014 | A1 |
20140188220 | Seguin | Jul 2014 | A1 |
20140253453 | Lo | Sep 2014 | A1 |
20140288642 | Yoshida et al. | Sep 2014 | A1 |
20140296908 | Ottma et al. | Oct 2014 | A1 |
20140296909 | Heipl et al. | Oct 2014 | A1 |
20140350592 | Kreidler et al. | Nov 2014 | A1 |
20140379019 | Larsen et al. | Dec 2014 | A1 |
20150005809 | Ayres et al. | Jan 2015 | A1 |
20150005810 | Center et al. | Jan 2015 | A1 |
20150051695 | Shaw | Feb 2015 | A1 |
20150135537 | Bruchman et al. | May 2015 | A1 |
20150223757 | Werneth et al. | Aug 2015 | A1 |
20150224231 | Bruchman et al. | Aug 2015 | A1 |
20150257875 | Bruchman | Sep 2015 | A1 |
20150257876 | Bruchman et al. | Sep 2015 | A1 |
20150265744 | Baaijens | Sep 2015 | A1 |
20150283297 | Baaijens et al. | Oct 2015 | A1 |
20150305749 | Alferness | Oct 2015 | A1 |
20150305862 | Bruchman et al. | Oct 2015 | A1 |
20150306277 | Pathak et al. | Oct 2015 | A1 |
20150366663 | Bruchman et al. | Dec 2015 | A1 |
20160008133 | Day et al. | Jan 2016 | A9 |
20160067374 | Puckett et al. | Mar 2016 | A1 |
20160074161 | Bennett | Mar 2016 | A1 |
20160100939 | Armstrong | Apr 2016 | A1 |
20160175095 | Dienno et al. | Jun 2016 | A1 |
20160175096 | Dienno | Jun 2016 | A1 |
20160317299 | Alkhatib | Nov 2016 | A1 |
20160331382 | Center et al. | Nov 2016 | A1 |
20170042674 | Armstrong | Feb 2017 | A1 |
20170181751 | Larsen et al. | Jun 2017 | A1 |
20180008406 | Bruchman et al. | Jan 2018 | A1 |
20180200050 | Bruchman et al. | Jul 2018 | A1 |
20190110880 | Fox et al. | Apr 2019 | A1 |
20190114303 | Peloski | Apr 2019 | A1 |
20190258641 | Peloski | Aug 2019 | A1 |
20190269506 | Bruchman et al. | Sep 2019 | A1 |
Number | Date | Country |
---|---|---|
1342056 | Mar 2002 | CN |
2820130 | Sep 2006 | CN |
2904980 | May 2007 | CN |
101304693 | Nov 2008 | CN |
101554343 | Oct 2009 | CN |
101780306 | Jul 2010 | CN |
101965161 | Feb 2011 | CN |
201879866 | Jun 2011 | CN |
201930098 | Aug 2011 | CN |
102908174 | Feb 2013 | CN |
103347467 | Oct 2013 | CN |
102014102725 | Sep 2015 | DE |
0150608 | Aug 1985 | EP |
0293090 | Nov 1988 | EP |
0313263 | Apr 1989 | EP |
0664107 | Jul 1995 | EP |
0679372 | Nov 1995 | EP |
0773971 | May 1997 | EP |
0815806 | Jan 1998 | EP |
0893108 | Jan 1999 | EP |
1318775 | Jun 2003 | EP |
1977719 | Oct 2008 | EP |
2074953 | Jul 2009 | EP |
2481381 | Aug 2012 | EP |
2596754 | May 2013 | EP |
2896405 | Jul 2007 | FR |
2344054 | May 2000 | GB |
02-000645 | Jan 1990 | JP |
08-126704 | May 1996 | JP |
H09501759 | Feb 1997 | JP |
09-241412 | Sep 1997 | JP |
11-290448 | Oct 1999 | JP |
2001-506902 | May 2001 | JP |
2002-503114 | Jan 2002 | JP |
2002-518086 | Jun 2002 | JP |
2004-510471 | Apr 2004 | JP |
2004-167239 | Jun 2004 | JP |
2004-188219 | Jul 2004 | JP |
2005530549 | Oct 2005 | JP |
2007-502689 | Feb 2007 | JP |
2007-518465 | Jul 2007 | JP |
2008506459 | Mar 2008 | JP |
2008-531117 | Aug 2008 | JP |
2009-542421 | Dec 2009 | JP |
2010-527742 | Aug 2010 | JP |
2010-535075 | Nov 2010 | JP |
2011-005292 | Jan 2011 | JP |
2011-509117 | Mar 2011 | JP |
2011-511693 | Apr 2011 | JP |
2011-516202 | May 2011 | JP |
2014-501563 | Jan 2014 | JP |
2014-501565 | Jan 2014 | JP |
2014-502180 | Jan 2014 | JP |
2014-533189 | Dec 2014 | JP |
2124986 | Jul 1996 | RU |
WO-9505555 | Feb 1995 | WO |
WO-9528899 | Nov 1995 | WO |
9618361 | Jun 1996 | WO |
WO-97010871 | Mar 1997 | WO |
9748350 | Dec 1997 | WO |
9826731 | Jun 1998 | WO |
9965420 | Dec 1999 | WO |
0013613 | Mar 2000 | WO |
WO-0041649 | Jul 2000 | WO |
0062716 | Oct 2000 | WO |
0121109 | Mar 2001 | WO |
0130266 | May 2001 | WO |
WO-0174272 | Oct 2001 | WO |
0224118 | Mar 2002 | WO |
0224119 | Mar 2002 | WO |
0228317 | Apr 2002 | WO |
WO-02060506 | Aug 2002 | WO |
WO-02100454 | Dec 2002 | WO |
0347468 | Jun 2003 | WO |
WO-2004000375 | Dec 2003 | WO |
2005072652 | Aug 2005 | WO |
2006007389 | Jan 2006 | WO |
WO-2006000763 | Jan 2006 | WO |
WO-2006019626 | Feb 2006 | WO |
2006091382 | Aug 2006 | WO |
2006127756 | Nov 2006 | WO |
WO-2007002320 | Jan 2007 | WO |
WO-2007016251 | Feb 2007 | WO |
2007092354 | Aug 2007 | WO |
2008006003 | Jan 2008 | WO |
WO-2008028964 | Mar 2008 | WO |
WO-2008036870 | Mar 2008 | WO |
2008047092 | Apr 2008 | WO |
WO-2008049045 | Apr 2008 | WO |
2008063464 | May 2008 | WO |
WO-2009017827 | Feb 2009 | WO |
WO-2009038761 | Mar 2009 | WO |
2009045332 | Apr 2009 | WO |
2009088905 | Jul 2009 | WO |
2009102441 | Aug 2009 | WO |
WO-2009100210 | Aug 2009 | WO |
2009126227 | Oct 2009 | WO |
2009148594 | Dec 2009 | WO |
WO-2009149462 | Dec 2009 | WO |
2010001012 | Jan 2010 | WO |
WO-2010006783 | Jan 2010 | WO |
2010024881 | Mar 2010 | WO |
WO-2010030766 | Mar 2010 | WO |
2010041038 | Apr 2010 | WO |
2010044854 | Apr 2010 | WO |
2010063795 | Jun 2010 | WO |
2010081041 | Jul 2010 | WO |
2010090699 | Aug 2010 | WO |
2010105195 | Sep 2010 | WO |
WO-2010132707 | Nov 2010 | WO |
2011031981 | Mar 2011 | WO |
2011062858 | May 2011 | WO |
WO-2011065809 | Jun 2011 | WO |
2012068257 | May 2012 | WO |
2012109297 | Aug 2012 | WO |
2012135603 | Oct 2012 | WO |
2012163257 | Dec 2012 | WO |
2012167131 | Dec 2012 | WO |
2013040431 | Mar 2013 | WO |
2013137977 | Sep 2013 | WO |
2015085138 | Jun 2015 | WO |
2015132668 | Sep 2015 | WO |
2016028591 | Feb 2016 | WO |
2016044223 | Mar 2016 | WO |
2016183495 | Nov 2016 | WO |
Entry |
---|
Annex to Form PCT/ISA/206 Communication Relating to the Results of the Partial International Search PCT/US2014/016550 dated Apr. 8, 2014, corresponding to U.S. Appl. No. 13/798,595; 3 pages. |
International Search Report and Written Opinion for PCT/US2011/061165 dated Oct. 1, 2012, corresponding to U.S. Appl. No. 13/298,060. |
International Search Report and Written Opinion for PCT/US2012/031417 dated Oct. 18, 2012, corresponding to U.S. Appl. No. 13/078,774. |
International Search Report and Written Opinion for PCT/US2012/040529 dated Nov. 14, 2012 corresponding to U.S. Appl. No. 13/485,823. |
International Search Report and Written Opinion for PCT/US2012/064908 dated Feb. 4, 2013, corresponding to U.S. Appl. No. 13/675,730, 11 pages. |
International Search Report and Written Opinion for PCT/US2012/064910 dated Feb. 1, 2013, corresponding to U.S. Appl. No. 13/675,764, 8 pages. |
International Search Report and Written Opinion for PCT/US2012/066518, dated Feb. 4, 2013, corresponding to U.S. Appl. No. 13/351,052, 12 pages. |
International Search Report and Written Opinion for PCT/US2014/016550 dated Jul. 2, 2014, corresponding to U.S. Appl. No. 13/798,595; 9 pages. |
International Search Report and Written Opinion for PCT/US2014/016581 dated Apr. 8, 2014, corresponding to U.S. Appl. No. 13/801,701, 4 pages. |
International Search Report and Written Opinion for PCT/US2014/016807 dated May 30, 2014, corresponding to U.S. Appl. No. 14/181,965, 4 pages. |
International Search Report and Written Opinion for PCT/US2015/042530 dated Oct. 6, 2015, corresponding to U.S. Appl. No. 14/622,599, 3 pages. |
International Search Report for PCT/US2012/065066, dated Nov. 11, 2013, corresponding to U.S. Appl. No. 13/675,959, 1 0 pages. |
Nakayama, Yasuhide. Microporous Stent Achieves Brain Aneurysm Occlusion Without Disturbing Branching Flow. NeuroNews Nov. 2012; 8:1-2. |
Partial International Search Report for PCT/US2012/065066, dated Jul. 1, 2013, corresponding to U.S. Appl. No. 13/675,959, 3 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2012/031417, dated Oct. 10, 2013, 5 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2012/040529, dated Dec. 12, 2013, 13 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/016550, dated Sep. 24, 2015, 16 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/016581, dated Sep. 24, 2015, 8 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/016794, dated Sep. 24, 2015, 7 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/016807, dated Sep. 24, 2015, 8 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/017118, dated Sep. 24, 2015, 9 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2015/042530, dated Aug. 24, 2017, 9 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2016/032487, dated Nov. 23, 2017, 13 pages. |
International Search Report and Written Opinion for PCT/US2012/061928 dated Jan. 22, 2013, corresponding to U.S. Appl. No. 13/658,597, 8 pages. |
International Search Report and Written Opinion for PCT/US2014/066153 dated Feb. 17, 2015, corresponding to U.S. Appl. No. 14/084,592, 5 pages. |
International Search Report and Written Opinion from PCT/US2016/032487, dated Dec. 14, 2016, 20 pages. |
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/017118, dated Jun. 6, 2014, 12 pages. |
International Search Report for PCT/US2014/016794 dated Jun. 6, 2014, corresponding to U.S. Appl. No. 14/182,044, 6 pages. |
International Written Opinion received for PCT Patent Application No. PCT/US2014/016794, dated Jun. 6, 2014, 5 pages. |
European Search Report and Search Opinion Received for EP Application No. 19179823.0, dated Oct. 1, 2019, 10 pages. |
International Preliminary Report on Patentability for PCT/US2012/055445 dated Mar 18, 2014, 9 pages. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2014/044258, dated Jan. 7, 2016, 7 pages. |
International Written Opinion received for PCT Patent Application No. PCT/US14/044258, dated Oct. 29, 2014, 5 pages. |
Nishi S, Nakayama Y, Ishibashi-Ueda H, Okamoto Y, Yoshida M. Development of microporous self-expanding stent grafts for treating cerebral aneurysms: designing micropores to control intimal hyperplasia. J Artif Organs 2011; 14:348-356. |
Number | Date | Country | |
---|---|---|---|
20170319338 A1 | Nov 2017 | US |
Number | Date | Country | |
---|---|---|---|
61779891 | Mar 2013 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14181965 | Feb 2014 | US |
Child | 15661549 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13485823 | May 2012 | US |
Child | 14181965 | US | |
Parent | 13078774 | Apr 2011 | US |
Child | 13485823 | US |